Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;140(2):134-9.
doi: 10.5858/arpa.2014-0612-OA.

Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population

Ryan J Gertz  1 , Yuri Nikiforov  2 , William Rehrauer  3 , Lee McDaniel  4 , Ricardo V Lloyd  3
Affiliations

Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population

Ryan J Gertz et al. Arch Pathol Lab Med. 2016 Feb.

Abstract

Context: Papillary thyroid carcinoma (PTC) is an uncommon tumor in the pediatric population. A limited number of studies have examined genetic mutations affecting the mitogen-activated protein kinase (MAPK) pathway in the pediatric population.

Objective: To examine mutations affecting this pathway in PTC in our pediatric population and compare the BRAF V600E mutation rates in pediatric and adult tumors.

Design: Eighty-four patients, including 14 pediatric and 70 adult, with PTC were tested for the BRAF V600E mutation by using real-time polymerase chain reaction and sequencing. Additionally, we examined the rate of RAS point mutations with real-time polymerase chain reaction and rearrangements of RET/PTC1 and RET/PTC3 in the pediatric group with fluorescence in situ hybridization. Clinical and histologic data were compared as well.

Results: Of 77 tumors that had an interpretable result, the BRAF V600E mutant was identified in 4 of 13 pediatric patients (31%) and 43 of 64 adult patients (67%), which was a significant difference (using Fisher exact test, P = .03). One pediatric and 6 adult cases did not reveal an interpretable result with melting curve analysis. One of these cases harbored a rare 3-base pair deletion mutation (c.1799_1801delTGA). Mutations in RAS genes were not seen in any pediatric tumors. One tumor with a RET/PTC1 rearrangement and another with RET/PTC3 were identified in the pediatric population (15%).

Conclusions: The rate of the BRAF V600E mutation in the pediatric population is significantly lower than that seen in the adult population. Mutations in RAS do not contribute significantly to pediatric PTC. This experience from our institution adds to the growing body of knowledge regarding tumor genetics in pediatric PTC.

PubMed Disclaimer

Figures

None
A and B, Papillary carcinoma with 3-bp deletion in BRAF (hematoxylin-eosin, original magnification ×40 [A and B]).
See this image and copyright information in PMC

References

    1. Hay I, Gonzalez-Losada T, Reinalda M, Honetschlager J, Richards M, Thompson G. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg. 2010;34(6):1192–1202. - PubMed
    1. Shayota B, Pawar S, Chamberlain R. MeSS: a novel prognostic scale specific for pediatric well-differentiated thyroid cancer: a population-based, SEER outcomes study. Surgery. 2013;154(3):429–435. - PubMed
    1. Miccoli P, Minuto M, Ugolini C, et al. Papillary thyroid cancer: pathological parameters as prognostic factors in different classes of age. Otolaryngol Head Neck Surg. 2008;138(2):200–203. - PubMed
    1. Zohar Y, Strauss M, Laurian N. Adolescent versus adult thyroid carcinoma. Laryngoscope. 1986;96(5):555–559. - PubMed
    1. Zimmerman D, Hay I, Gough I, et al. Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery. 1988;104(6):1157–1166. - PubMed

Publication types

MeSH terms